Silence Therapeutics Earns $4M Milestone Payment from Hansoh Pharma Collaboration

“We are very pleased with the continued progress being made in our Hansoh Pharma collaboration,” said Craig Tooman, President and CEO of Silenc...

July 12, 2023 | Wednesday | News
Advanced FDA Cleared Magstim Horizon 3.0 TMS Now Available in United Kingdom

The advanced and FDA-cleared Magstim Horizon 3.0 transcranial magnetic stimulation (TMS) system is now UKCA registered and available for sale in the UK, pr...

July 10, 2023 | Monday | News
Carrick Therapeutics collaborates with Arvinas and Pfizer for clinical trial on Samuraciclib and Vepdegestrant combination

Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today announced a clinical ...

July 07, 2023 | Friday | News
Biocytogen Pharmaceuticals Enters Into License Agreement With Pheon Therapeutics

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), a global biotech company focusing on the discovery of novel antibody therapeuti...

July 06, 2023 | Thursday | News
Paras Biopharma Enhances Protein Expression in Microbial Systems for Cost-effective Biologics Production

The company is pleased to disclose its advancement of up to 12 g or more / L expression of recombinant protein - fully folded / biologically active in ferm...

July 04, 2023 | Tuesday | News
Camena Bioscience Raises $10M in Series A Funding Amid Growing DNA Synthesis Demand

Funding will be used to scale operations and continue development of its pioneering DNA synthesis platform, gSynth™ Funding round led by Mercia C...

July 04, 2023 | Tuesday | News
Novo Nordisk A/S - share repurchase programme

Under the programme initiated 9 May 2023, Novo Nordisk will repurchase B shares for an amount up to DKK 5.8 billion in the period from 10 May 2023 to 8 Aug...

July 04, 2023 | Tuesday | News
Sandoz Launches Hyrimoz® High-Concentration Formulation in US Immunology Space

Hyrimoz® (adalimumab-adaz) high-concentration formulation (HCF) biosimilar offers US patients reduced injection volume in citrate-free formulation A...

July 03, 2023 | Monday | News
Bayer initiates Phase III studies with investigational contrast agent gadoquatrane

Gadoquatrane is a highly stable contrast agent for magnetic resonance imaging (MRI) with high relaxivity and the potential of a substantially lower gadol...

June 28, 2023 | Wednesday | News
Genmab and AbbVie Report Positive Results from EPCORE™ NHL-1 Trial for Epcoritamab in Relapsed/Refractory Follicular Lymphoma

Based on the topline results from the EPCORE™ NHL-1 clinical trial, Genmab and AbbVie will engage with global regulatory authorities to discuss nex...

June 28, 2023 | Wednesday | News
Oncodesign Services announce access to ImaginAb’s CD8 ImmunoPET™ technology

By using this cutting-edge imaging technology in preclinical studies, Oncodesign Services’ team hopes to gain insights of the predictive effectivenes...

June 28, 2023 | Wednesday | News
TLX250-CDx Shows Potential Utility in ccRCC Staging: New ZIRCON Phase III Data Presented in Australia.

New data demonstrates the ability of TLX250-CDx to detect extrarenal lesions, supporting potential clinical utility in the metastatic or recurrent setting,...

June 27, 2023 | Tuesday | News
Bristol Myers Squibb Gets European Commission Approval for CAMZYOS® in Treating Symptomatic Obstructive HCM

CAMZYOS is the first and only cardiac myosin inhibitor approved in the European Union Approval based on two positive Phase 3 trials, EXPLORER-HCM and VALO...

June 27, 2023 | Tuesday | News
ERYTECH and PHERECYDES announce merger and name change to PHAXIAM Therapeutics

Merger approved with large majority by the shareholders of both companies New governance structure implemented Ambition to create a global leader in ex...

June 27, 2023 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close